Apr 1996 - Present
BioVest Advisors LLC
The Rosalind Franklin University of Medicine and Science / The Chicago Medical School
Washington & Lee University
In his position as President of Beverly Hills-based BioVest Advisors LLC, Richard W. Bank, MD, 67, draws on decades of experience in biotechnology and an extensive database of more than 1,200 buy- and sell-side investment contacts. These include private equity funds, hedge funds, and venture capital firms. He also maintains access to capital funding sources in Switzerland and the United Kingdom.
Richard W. Bank, MD, began his career as a physician more than three decades ago. Receiving his medical degree from The Chicago Medical School at the Finch University of Health Sciences, (now Rosalind Franklin University) he undertook an internship at the University of California, San Francisco, and residencies at the Johns Hopkins School of Medicine in Baltimore and the Mount Sinai Hospital in Baltimore, Maryland. Dr. Bank subsequently served as Attending Physician at Cedars-Sinai in Los Angeles, holding this position until 1995. Currently a Clinical Professor Emeritus in the University of Southern California School of Medicine’s Department of Obstetrics and Gynecology, he has been active as a faculty member of the institution for the past 30 years.
In 1986, Dr. Bank co-founded the biotechnology company USAT, which developed an anonymous and confidential at-home AIDS testing product. After receiving FDA premarket approval, the product had its launch delayed due to the firm’s sale. Richard W. Bank, MD, established the dedicated life science hedge fund First-Tier Biotechnology Partners in 1995, serving as President, Managing Director, and Portfolio Manager. The company was acquired by Lehman Brothers Holdings, Inc. in 2004.
From 2004 to 2006, Richard W. Bank, MD, served as Senior Portfolio Manager, Managing Director, and Senior Vice President of Liberty View Health Sciences Fund, a division of Liberty View Capital Management (a Lehman Brothers Holdings, Inc. company). Dr. Bank undertook additional duties from 1998 to 1999 as Senior Equity Analyst and Director of Biotechnology at SBC Warburg Dillon Read (since acquired by Swiss financial services firm UBS AG). He also served as President and Secretary of BioVest Health Sciences, Inc. from 1996 to 2004.
In addition to his executive-level positions with financial firms, Richard W. Bank, MD, has consulted on behalf of numerous biotechnology companies, including Guilford Pharmaceuticals, Inc., Bradmer Pharmaceuticals Inc., Protein Design Labs Inc., and Athersys Pharmaceuticals Inc. He holds a board position with Vigilnet America LLC, and has served as Director of the publicly traded biotechnology company PolyMedix, Inc., since 2008. For more than a decade, Richard W. Bank, MD, has attended a wide range of medical and life sciences conferences held by major investment banks.
Richard W Bank, MD, 68 years old, is the president of BioVest Advisors, LLC. The company, which was established to promote medical research and new therapies, is constantly seeking investments that will enable doctors to provide innovative care in the field of neuro-oncology. Richard W Bank, MD, is a strong advocate of this area of medicine.Neuro-oncology is a field of medicine that involves the study of life-threatening neoplasms of the brain and spinal cord. Unfortunately, the prognosis is not usually good for those who have brain cancer as the survival rate does not go beyond several months without treatment. Furthermore, it extends no further than 18 to 24 months when chemotherapy and radiation are applied. While surgery has proven to provide a cure in some instances, the cancer typically eventually reemerges.However, several technologies now exist that make it possible for patients to undergo therapy for tumors that were previously untreatable. One noninvasive procedure, gamma knife radiosurgery, delivers high doses of radiation to a targeted area without affecting the surrounding tissues. Laser interstitial thermal treatments are also utilized. They use an MRI-directed laser to destroy brain tumors, such as glioblastoma, which was previously one of the most difficult cancers to treat.
Richard W. Bank, MD, is a 67-year-old executive who founded First-Tier Biotechnology Partners in 1995. He went on to serve as the company’s president, managing director, and portfolio manager. During his time with First-Tier Biotechnology Partners, Richard W. Bank, MD, also worked as the director of biotechnology for SBC Warburg Dill Read (UBS).Recent health reform legislation has placed a major emphasis on the general public’s access to quality healthcare. Part of this initiative involves delivering the value of metropolitan-area medicine to less populated regions of the country. Automated medical technology, also known as Telemedicine, has taken a huge step toward achieving this goal, but medical robots will take medicine even further in coming years.Comprehensive robotic check-ups are now able to make routine rounds throughout hospital floors, checking on individual patients and monitoring vitals with little to no human intervention. iRobot Corp. and InTouch Health have collaborated on the first medical robot to receive FDA approval, the RP-VITA Remote Presence Robot. The robot consists of a two-way video screen, medical monitoring equipment, and acute motion sensitivity that allows the robot to move through crowded hospital hallways.